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Summary 
FGFR2 genetic translocations are frequent in cholangiocarcinoma, yet despite initial 
sensitivity to FGFR inhibitors in clinic, patients quickly become resistant to targeted 
therapies. The work published by Goyal and colleagues demonstrates that 
acquisition of gatekeeper mutations in FGFR2 and intra-tumoral heterogeneity drive 
resistance in patients with FGFR2-translocated intrahepatic cholangiocarcinoma, 
which will have important implications for management of the disease in clinic.  
 
Editorial 
Oncogenic chromosomal rearrangements in the fibroblast growth factor receptors 
(FGFRs) present a potential therapeutic target, with translocations in FGFR2 found 
most frequently in cholangiocarcinoma (1,2) and translocations in FGFR3 prevalent 
in bladder and glioblastoma (2). Preclinical models of these fusion proteins have 
demonstrated sensitivity to FGFR inhibitors, and recent data from early phase 
clinical trials substantiated these findings in the clinic (3-5).  However the extent of 
these translocations as true oncogenic drivers, and the potential mechanisms of 
resistance to therapy, have previously only been investigated preclinically. Goyal et 
al(6) demonstrate FGFR2 translocations in intrahepatic cholangiocarcinoma (ICC) 
are classic oncogene drivers, with response to FGFR inhibition in the clinic followed 
by development of common gatekeeper mutations in FGFR2 resulting in clinical 
resistance.  
 
Cholangiocarcinoma has historically been dichotomised by anatomical location into 
intra- and extra-hepatic subtypes. Recent developments in genomic and 
transcriptomic technologies have revealed fundamental molecular differences 
between these anatomic sub-sites, reflecting distinct aetiologies (7). Intrahepatic 
cholangiocarcinoma, a disease with growing incidence for yet unknown reasons, 
harbours FGFR2 translocations in up to 16% of cases (1,2).  Fusion proteins 
generated by genetic translocations generally fuse a variety of protein fragments to 
the cytoplasmic tail of FGFR2, thereby deleting the C-terminus. The fusion partners 
usually contain protein-binding domains, which most likely induce constitutive 
dimerization and ligand-independent activation of the FGFR kinase domain (2). 
Overexpression of FGFR fusion proteins results in increased sensitivity to FGFR 
inhibitors in vitro and in vivo models (2). Furthermore, early phase clinical trials have 
demonstrated clinical activity with a number of selective FGFR inhibitors, including 
JNJ-42756493(3), AZD4547(5), and NVP-BGJ398(4).  In previously treated FGFR2-
translocated cholangiocarcinoma patients, the selective pan-FGFR inhibitor NVP-
BGJ398 revealed an objective response rate of 22% and median duration of 
treatment of approximately six months (4). As progression-free survival in most 
second line cholangiocarcinoma studies is in the region of three months, these 
results are promising.    
 
Despite these encouraging findings, FGFR2-translocated cholangiocarcinoma 
tumours appear to relatively swiftly develop acquired resistance to FGFR inhibitors.   
In this issue of Cancer Discovery, Goyal and colleagues report on a proposed 
mechanism of resistance to FGFR inhibition in three patients treated with NVP-
BGJ398. Although the number of patients studied is small, these patients revealed 
consistent acquisition of gatekeeper mutations in FGFR2 and polyclonal resistance 
reflective of diverse intra-tumoural genetic heterogeneity in cholangiocarcinoma.  
 
Using molecular barcoded sequencing on progression plasma DNA and tumour, they 
describe the acquisition of polyclonal FGFR2 mutations, with a gatekeeper p.V564F 
mutation found in all three patients. Mutations at this residue had been identified as 
potential gatekeeper mutation in prior preclinical studies (8,9), and this study 
confirms the importance of p.V564 residue in mediating resistance to targeted 
therapy. In total, the study identified three FGFR2 mutations that were common 
(p.N549H, p.V564F, and p.E565A, all in the kinase domain of the receptor) and 
further mutations unique to individual patients.  Using computational modelling and 
functional in vitro studies, the authors show that the mutations identified have the 
potential to hinder binding of NVP-BJG398 either through stabilizing the kinase in an 
active or inactive conformation, producing an unfavourable binding conformation, or 
direct steric hindrance such as that created by the commonly present p.V564F 
gatekeeper mutation.    
 
Goyal et al. identified two other major factors contributing to resistance. Intra-tumoral 
genetic heterogeneity contributed substantially to acquired resistance in at least two 
of the three patients, although FGFR2 p.V564F was the only selected mutation 
detected in plasma, in the patient with the longest duration of response. Overt 
geographical intra-tumoural heterogeneity was further demonstrated from multi-
region sequencing of a rapid autopsy, with lesion-specific acquisition of distinct 
resistance mutations. The study suggests that ICC has substantial intra-tumoral 
genetic heterogeneity, which presents a major challenge to targeted therapy for 
these cancers. Amongst the lesion-specific mutations identified, acquired genetic 
loss of PTEN was selected in multiple lesions, confirming prior preclinical 
observation that silencing PTEN reduced sensitivity to FGFR inhibitors in FGFR2-
amplified cancers (10). 
  
The study provides a rationale for developing third generation inhibitors that target 
FGFR2_V564F and other common mutations, to treat resistant tumours or cut-off 
one of the mechanisms to acquired resistance. Goyal et al. also profiled currently 
available first- and second-generation FGFR inhibitors to identify which may be more 
active against gatekeeper mutations. Here, the authors switched to using TEL-
FGFR3 fusions in BaF3 cell lines for inhibitor screening. Although the kinase 
domains of FGFR2 and FGFR3 are highly similar, the use of FGFR3 as a model is a 
clear weakness in the manuscript. Nevertheless, the results are interesting. 
Polyclonal gatekeeper mutations develop in acquired resistant TEL-FGFR3 at low 
doses of NVP-BGJ398, but at higher doses only V555M mutation develops 
(equivalent to V564 in FGFR2). The authors proceeded to evaluate the differential 
sensitivity of BaF3 cells expressing FGFR3 resistance mutation to several other 
FGFR inhibitors, of which pan-FGFR inhibitor LY2874455 displayed the most activity 
against cells harbouring TEL-FGFR3_V555M mutant, and also in FGFR2_V564F. 
This finding may have direct clinical relevance in terms of treatment sequencing for 
cholangiocarcinoma patients in future.  
 
The contribution of Goyal and colleagues to the field of FGFR2-translocated 
cholangiocarcinoma is important. Although the manuscript is limited by small sample 
size, shared gatekeeper mutations were characterized. Identification of similar 
gatekeeper mutations in EGFR and ALK-positive lung cancer has led to 
development of superior second and third generation EGFR and ALK tyrosine kinase 
inhibitors and improved survival for non-small cell lung cancer patients. It will be 
important to extend these observations into more patients, and into other pan-FGFR 
tyrosine kinase inhibitors. Identification of gatekeeper mutations confirms beyond 
doubt that cholangiocarcinomas are addicted to translocated FGFR2, emphasising 
the pressing clinical need to move inhibitors forward to pivotal studies. A more 
fundamental question that the current study raises is the utility of post-progression 
biopsies to evaluate mechanisms of resistance in the face of gross tumour 
heterogeneity.  As the sensitivity of circulating DNA sequencing increases, this tool 
may become the primary method through which the genomic evolution of tumours is 
evaluated, as the limitations imposed by the spatial boundaries of biopsies may 
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